ESTRO 2024 - Abstract Book

S485

Clinical - Breast

ESTRO 2024

The median follow-up was 35.6 months (range 4.0-132.9 months). The LRFS at 1 year and 2 years were 90.9% and 88.7%. The estimated median PFS was 19.2 months (95%CI 10.3-28.1 months); the PFS at 1 year and 2 years were 63.3% and 44.4%. The estimated OS at 1 year and 2 years were 98.0% and 91.9% respectively with the estimated median OS of 105.1 months (95%CI 51.5-158.7 months). The estimated OS at 1 year and 2 years were 98.0% and 91.9% respectively with the estimated median OS of 105.1 months (95%CI 51.5-158.7 months). The vast majority of patient tolerated the treatment well with the commonest acute side effects as grade 1 fatigue. There were no